Explore the words cloud of the ADVaNCE project. It provides you a very rough idea of what is the project "ADVaNCE" about.
The following table provides information about the project.
Coordinator |
EDELWEISS CONNECT GMBH
Organization address contact info |
Coordinator Country | Switzerland [CH] |
Project website | https://github.com/tadoktor/HCC-study |
Total cost | 187˙419 € |
EC max contribution | 187˙419 € (100%) |
Programme |
1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility) |
Code Call | H2020-MSCA-IF-2016 |
Funding Scheme | MSCA-IF-EF-SE |
Starting year | 2017 |
Duration (year-month-day) | from 2017-10-01 to 2019-09-30 |
Take a look of project's partnership.
# | ||||
---|---|---|---|---|
1 | EDELWEISS CONNECT GMBH | CH (BASEL) | coordinator | 187˙419.00 |
The field of toxicology is evolving from purely descriptive to a highly dataâ€rich science. To structure this large amount of data and in this way make the usage more effective for the safety assessors, the concept of adverse outcome pathways was established providing a means of understanding how chemicals induce adverse effects through their toxicity pathways and modes of action. However, there are some doubts if the one initiating event - one adverse outcome relationship enforced on AOPs by the OECD guideline is able to cover more complex adverse effects like hepatocellular carcinoma resulting from non-mutagenic chemical exposure. Therefore, the ADVaNCE project will demonstrate based on the just mentioned example that combining all existing knowledge into an adverse outcome network formed by interlinked AOPs is needed to cover all the pathways and intervention points activated in order to contribute to the development of hepatocellular carcinomas. Computational approaches will be used to extract important key events and their relationships from existing data sources and the relevant literature. These will be compared with existing AOPs and further experimental validation will be started. The computational and experimental result will finally guide the development of an integrated testing strategy completely based on in silico and in vitro data, which development and validation regarding regulatory usage will be continued after the project.
year | authors and title | journal | last update |
---|---|---|---|
2018 |
Oana Florean, Lucian Farcal, Noffisat Oki, Thomas Exner, Barry Hardy and Tatyana Doktorova Use of publicly available transcriptomics data to support the steatosis AOP development published pages: , ISSN: 1868-596X, DOI: |
2020-04-14 | |
2019 |
Tatyana Y. Doktorova, Noffisat O. Oki, Tomaž MohoriÄ, Thomas E. Exner, Barry Hardy An automated workflow for Adverse Outcome Pathway hypothesis generation: the use case of non-genotoxic induced hepatocellular carcinoma published pages: , ISSN: 0273-2300, DOI: |
Regulatory Toxicology and Pharmacology (submitted) | 2020-04-14 |
2019 |
Noffisat O. Oki, Lucian Farcal, Ahmed Abdelaziz, Oana Florean, Tatyana Y. Doktorova, Thomas Exner, Pekka Kohonen, Roland Grafström, Barry Hardy Integrated analysis of in vitro data and the adverse outcome pathway framework for prioritization and regulatory applications: An exploratory case study using publicly available data on piperonyl butoxide and liver models published pages: 23-32, ISSN: 0887-2333, DOI: 10.1016/j.tiv.2018.09.002 |
Toxicology in Vitro 54 | 2020-04-14 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ADVANCE" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "ADVANCE" are provided by the European Opendata Portal: CORDIS opendata.